Data di Pubblicazione:
2021
Abstract:
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Teerlink, John R; Diaz, Rafael; Felker, G Michael; Mcmurray, John J V; Metra, Marco; Solomon, Scott D; Adams, Kirkwood F; Anand, Inder; Arias-Mendoza, Alexandra; Biering-Sørensen, Tor; Böhm, Michael; Bonderman, Diana; Cleland, John G F; Corbalan, Ramon; Crespo-Leiro, Maria G; Dahlström, Ulf; Echeverria, Luis E; Fang, James C; Filippatos, Gerasimos; Fonseca, Cândida; Goncalvesova, Eva; Goudev, Assen R; Howlett, Jonathan G; Lanfear, David E; Li, WEN JING; Lund, Mayanna; Macdonald, Peter; Mareev, Viacheslav; Momomura, Shin-Ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J A; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A; Yilmaz, Mehmet B; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C; Varin, Claire; Honarpour, Narimon; Abbasi, Siddique A; Malik, Fady I; Kurtz, Christopher E
Link alla scheda completa:
Pubblicato in: